See more : Eqonex Limited (EQOSQ) Income Statement Analysis – Financial Results
Complete financial analysis of Cryo-Cell International, Inc. (CCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cryo-Cell International, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Amprius Technologies, Inc. (AMPX-WT) Income Statement Analysis – Financial Results
- Kakaku.com, Inc. (2371.T) Income Statement Analysis – Financial Results
- Gseven Co., Ltd. (2937.TWO) Income Statement Analysis – Financial Results
- Cascadero Copper Corporation (CCEDF) Income Statement Analysis – Financial Results
- Jenkem Technology Co., Ltd. (688356.SS) Income Statement Analysis – Financial Results
Cryo-Cell International, Inc. (CCEL)
About Cryo-Cell International, Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.34M | 30.34M | 28.88M | 31.15M | 31.82M | 29.22M | 25.38M | 23.13M | 21.09M | 20.13M | 18.99M | 17.97M | 17.92M | 17.64M | 16.33M | 17.28M | 17.46M | 17.18M | 14.45M | 12.21M | 7.55M | 7.07M | 5.65M | 2.11M | 1.70M | 300.00K | 400.00K | 2.70M |
| Cost of Revenue | 8.44M | 8.79M | 8.99M | 9.66M | 10.04M | 8.54M | 6.72M | 5.77M | 5.63M | 5.63M | 5.32M | 4.89M | 4.40M | 4.50M | 4.53M | 6.11M | 6.59M | 6.07M | 4.14M | 3.16M | 2.63M | 2.50M | 1.66M | 827.33K | 200.00K | 200.00K | 0.00 | 300.00K |
| Gross Profit | 22.90M | 21.54M | 19.90M | 21.49M | 21.78M | 20.68M | 18.66M | 17.35M | 15.46M | 14.49M | 13.67M | 13.08M | 13.52M | 13.13M | 11.79M | 11.16M | 10.87M | 11.11M | 10.31M | 9.05M | 4.92M | 4.58M | 3.99M | 1.28M | 1.50M | 100.00K | 400.00K | 2.40M |
| Gross Profit Ratio | 73.07% | 71.02% | 68.88% | 68.99% | 68.46% | 70.77% | 73.51% | 75.03% | 73.30% | 72.02% | 71.98% | 72.80% | 75.45% | 74.46% | 72.24% | 64.62% | 62.24% | 64.68% | 71.33% | 74.10% | 65.23% | 64.72% | 70.68% | 60.78% | 88.24% | 33.33% | 100.00% | 88.89% |
| Research & Development | 1.17M | 384.79K | 49.87K | 23.85K | 30.15K | 91.85K | 41.17K | 53.10K | 45.78K | 64.37K | 36.17K | 109.64K | 184.05K | 132.99K | 102.41K | 194.46K | 545.49K | 486.16K | 26.15K | 82.51K | 226.68K | 219.66K | 51.07K | 275.80K | 100.00K | 400.00K | 200.00K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.63M | 13.48M | 14.72M | 12.39M | 12.25M | 11.37M | 14.43M | 12.41M | 9.49M | 8.94M | 10.83M | 14.46M | 12.96M | 9.10M | 6.27M | 9.71M | 6.06M | 3.95M | 2.85M | 2.30M | 1.90M | 1.80M | 1.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.12M | 15.58M | 14.63M | 14.29M | 14.89M | 15.63M | 13.48M | 14.72M | 12.39M | 12.25M | 11.37M | 14.43M | 12.41M | 9.49M | 8.94M | 10.83M | 14.46M | 12.96M | 9.10M | 6.27M | 9.71M | 6.06M | 3.95M | 2.85M | 2.30M | 1.90M | 1.80M | 1.50M |
| Other Expenses | 16.92M | 1.12M | 834.85K | 166.44K | 206.24K | -24.72K | -79.87K | -14.67K | 22.99K | 210.26K | 48.85K | 204.15K | 571.41K | 294.06K | 1.08M | 408.77K | 532.31K | 629.15K | -45.87K | -488.89K | 2.51M | 3.84M | 476.48K | 313.49K | 100.00K | 200.00K | 100.00K | 100.00K |
| Operating Expenses | 35.21M | 17.08M | 15.51M | 14.48M | 15.13M | 15.90M | 13.65M | 14.93M | 12.53M | 12.49M | 11.59M | 14.74M | 13.17M | 9.91M | 10.12M | 11.43M | 15.54M | 14.07M | 9.08M | 5.87M | 12.45M | 10.12M | 4.48M | 3.44M | 2.50M | 2.50M | 2.10M | 1.60M |
| Cost & Expenses | 43.65M | 25.88M | 24.50M | 24.14M | 25.16M | 24.44M | 20.38M | 20.71M | 18.16M | 18.12M | 16.91M | 19.63M | 17.57M | 14.42M | 14.65M | 17.54M | 22.13M | 20.14M | 13.23M | 9.03M | 15.07M | 12.61M | 6.13M | 4.27M | 2.70M | 2.70M | 2.10M | 1.90M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.91K | 26.30K | 71.64K | 154.82K | 318.01K | 322.37K | 143.50K | 47.51K | 53.24K | 128.27K | 110.77K | 121.84K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.24M | 1.52M | 1.38M | 1.54M | 1.70M | 1.55M | 1.30M | 947.34K | 1.30M | 1.15M | 1.40M | 1.02M | 1.46M | 1.28M | 1.42M | 1.32M | 1.39M | 1.02M | 863.71K | 750.13K | 655.73K | 58.85K | 10.48K | 2.21K | 0.00 | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.71M | 1.81M | 1.33M | 635.98K | 401.31K | 317.33K | 230.00K | 286.65K | 241.21K | 377.01K | 394.50K | 466.74K | 579.85K | 580.19K | 671.82K | 678.15K | 741.77K | 724.52K | 597.37K | 657.38K | 452.58K | 802.45K | 512.63K | 313.49K | 100.00K | 200.00K | 100.00K | 100.00K |
| EBITDA | -10.42M | 6.65M | 5.32M | 7.22M | 5.50M | 5.48M | 5.16M | -1.25M | 2.49M | 2.21M | 1.99M | -1.35M | 112.99K | 3.65M | 3.63M | 1.38M | -3.93M | -2.24M | 1.82M | 3.84M | -6.33M | -5.16M | 26.74K | -1.85M | -900.00K | -2.00M | -1.40M | 900.00K |
| EBITDA Ratio | -33.24% | 20.67% | 19.77% | 24.54% | 22.27% | 17.34% | 20.31% | 11.65% | 15.07% | 11.09% | 12.48% | -7.49% | 5.40% | 20.67% | 22.26% | 2.33% | -28.02% | -17.54% | 4.91% | 17.91% | -77.69% | -29.74% | -20.91% | -113.70% | -82.35% | -733.33% | -425.00% | 37.04% |
| Operating Income | -12.30M | 4.02M | 4.00M | 7.66M | 5.06M | 5.19M | 5.01M | 433.59K | 2.93M | 1.98M | 1.70M | -1.71M | -276.74K | 3.22M | 1.67M | -326.75K | -4.67M | -2.96M | 1.22M | 3.18M | -7.52M | -5.54M | -485.89K | -2.16M | -1.00M | -2.40M | -1.70M | 800.00K |
| Operating Income Ratio | -39.26% | 13.27% | 13.86% | 24.60% | 15.91% | 17.76% | 19.72% | 1.87% | 13.91% | 9.84% | 8.96% | -9.52% | -1.54% | 18.27% | 10.24% | -1.89% | -26.76% | -17.23% | 8.47% | 26.04% | -99.64% | -78.28% | -8.60% | -102.45% | -58.82% | -800.00% | -425.00% | 29.63% |
| Total Other Income/Expenses | -1.06M | -705.52K | -1.41M | -2.62M | -1.67M | -1.57M | -1.38M | -2.91M | -1.98M | -1.30M | -1.51M | -2.71M | -1.65M | -1.38M | -1.46M | -294.33K | -332.75K | 232.98K | -106.79K | -160.71K | -739.11K | -349.48K | 485.89K | 550.75K | 500.00K | 0.00 | 100.00K | -100.00K |
| Income Before Tax | -13.36M | 3.32M | 2.61M | 5.04M | 3.39M | 3.62M | 3.62M | -2.48M | 949.52K | 677.15K | 197.02K | -4.42M | -1.70M | 1.78M | 1.55M | -760.42K | -5.01M | -2.73M | 1.12M | 3.02M | -7.52M | -5.17M | 775.95K | -1.61M | -500.00K | 0.00 | -1.60M | 700.00K |
| Income Before Tax Ratio | -42.64% | 10.94% | 9.04% | 16.18% | 10.66% | 12.38% | 14.28% | -10.72% | 4.50% | 3.36% | 1.04% | -24.60% | -9.47% | 10.09% | 9.47% | -4.40% | -28.67% | -15.87% | 7.73% | 24.72% | -99.62% | -73.04% | 13.74% | -76.34% | -29.41% | 0.00% | -400.00% | 25.93% |
| Income Tax Expense | -3.84M | 547.54K | 527.71K | 1.41M | 1.10M | 4.47M | 1.31M | -1.16M | -7.16M | 123.53K | 169.58K | 1.89M | 171.94K | -1.63M | 121.81K | 494.41K | 332.75K | -148.70K | -36.00K | 86.00K | 1.10K | 161.50K | -1.39M | -670.37K | -400.00K | -100.00K | -100.00K | 200.00K |
| Net Income | -9.52M | 2.77M | 2.08M | 3.62M | 2.29M | -854.82K | 2.32M | -1.32M | 8.11M | 553.62K | 27.44K | -6.31M | -2.10M | 3.41M | 1.42M | -760.42K | -5.01M | -2.81M | 1.03M | 2.84M | -7.52M | -5.33M | 899.63K | -1.49M | -600.00K | -2.30M | -1.60M | 600.00K |
| Net Income Ratio | -30.38% | 9.14% | 7.21% | 11.64% | 7.20% | -2.93% | 9.12% | -5.71% | 38.43% | 2.75% | 0.14% | -35.11% | -11.69% | 19.34% | 8.73% | -4.40% | -28.67% | -16.36% | 7.15% | 23.26% | -99.63% | -75.32% | 15.93% | -70.67% | -35.29% | -766.67% | -400.00% | 22.22% |
| EPS | -1.14 | 0.33 | 0.26 | 0.48 | 0.29 | -0.11 | 0.33 | -0.16 | 0.85 | 0.05 | 0.00 | -0.56 | -0.18 | 0.29 | 0.12 | -0.06 | -0.43 | -0.24 | 0.09 | 0.25 | -0.66 | -0.47 | 0.09 | -0.15 | -0.07 | -0.32 | -0.23 | 0.09 |
| EPS Diluted | -1.14 | 0.33 | 0.25 | 0.45 | 0.27 | -0.11 | 0.30 | -0.16 | 0.83 | 0.05 | 0.00 | -0.56 | -0.18 | 0.29 | 0.12 | -0.06 | -0.43 | -0.24 | 0.08 | 0.24 | -0.66 | -0.47 | 0.09 | -0.15 | -0.07 | -0.32 | -0.23 | 0.09 |
| Weighted Avg Shares Out | 8.34M | 8.47M | 8.14M | 8.14M | 8.41M | 7.46M | 7.06M | 8.11M | 9.54M | 10.18M | 10.86M | 11.31M | 11.76M | 11.75M | 11.75M | 11.73M | 11.66M | 11.62M | 11.58M | 11.37M | 11.35M | 11.34M | 10.58M | 9.76M | 8.21M | 7.28M | 6.96M | 7.18M |
| Weighted Avg Shares Out (Dil) | 8.34M | 8.48M | 8.36M | 8.14M | 8.41M | 7.46M | 7.65M | 8.11M | 9.80M | 10.43M | 10.97M | 11.31M | 11.76M | 11.81M | 11.80M | 11.73M | 11.66M | 11.62M | 12.23M | 11.91M | 11.35M | 11.34M | 10.58M | 9.76M | 8.21M | 7.28M | 6.96M | 7.18M |
Cryo-Cell International to Present at the Q3 Virtual Investor Summit on August 18, 2021
Oldsmar, Florida--(Newsfile Corp. - August 11, 2021) - Cryo-Cell International (OTC Pink: CCEL) today announced that David Portnoy, Chairman of the board and Co-CEO will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 18th at 02:45 PM...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2021 Financial Results
OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter...
Cryo-Cell International: Overlooked Duke Contract Signals Business Inflection
CCEL is undervalued, given the overlooked Duke contract.
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against Cryo-Cell International, Inc. and Advises Investors to Contact the Firm
IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP announces that it is investigating claims against Cryo-Cell International, Inc. (“Cryo-Cell” or the “Company”) (OTC MKTS: CCEL). The investigation focuses on whether the Company and its officers violated Delaware law. If you purchased shares...
SHAREHOLDER ALERT: Lundin Law PC Announces Ongoing Investigation Of Cryo-Cell International, Inc. And Advises Investors With Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces it is investigating claims against Cryo-Cell International, Inc. (“Cryo-Cell” or the “Company”) (OTC MKTS: CCEL) concerning possible violations of Delaware law. To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of...
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Cryo-Cell International, Inc. and Advises Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces it is investigating claims against Cryo-Cell International, Inc. (“Cryo-Cell” or the “Company”) (OTC MKTS: CCEL) concerning possible violations of Delaware law. To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Violations of Delaware Law by Certain Officers and Directors of Cryo-Cell International, Inc.
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Cryo-Cell International, Inc. (OTC MKTS:CCEL) concerning possible violations of Delaware law. To obtain additional information about the investigation, go to: http://zlk.9nl.com/cryo-cell-international-ccel or contact Eduard Korsinsky, Esq. either via...
Cryo-Cell Announces Results of 2011 Election of Board of Directors
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (OTCQX:CCEL ) is pleased to announce that the independent inspector of elections engaged by the Company, IVS Associates, Inc., has certified that at the Annual Meeting of Shareholders held on August 25, 2011 the shareholders...
CORRECTING and REPLACING Letter From Portnoy Group to Cryo-Cell Shareholders
BAL HARBOUR, Fla.--(BUSINESS WIRE)--Reissuing release dated August 17, 2011 to add ticker symbol for searching purposes. The release reads: LETTER FROM PORTNOY GROUP TO CRYO-CELL SHAREHOLDERS LET THE TRUTH BE KNOWN Cryo-Cell’s hometown newspaper, The Tampa Bay Business Journal, ran...
Source: https://incomestatements.info
Category: Stock Reports